Barclays PLC Raises Position in Pacific Biosciences of California (NASDAQ:PACB)

Barclays PLC raised its stake in shares of Pacific Biosciences of California (NASDAQ:PACB) by 93.2% during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 555,594 shares of the biotechnology company’s stock after purchasing an additional 267,982 shares during the period. Barclays PLC owned 0.36% of Pacific Biosciences of California worth $2,866,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds also recently modified their holdings of the company. Cubist Systematic Strategies LLC purchased a new stake in Pacific Biosciences of California during the second quarter valued at approximately $28,000. Point72 Hong Kong Ltd bought a new position in shares of Pacific Biosciences of California during the second quarter valued at approximately $37,000. Quest Capital Management Inc. ADV bought a new position in shares of Pacific Biosciences of California during the third quarter valued at approximately $39,000. FNY Investment Advisers LLC grew its stake in shares of Pacific Biosciences of California by 211.1% during the second quarter. FNY Investment Advisers LLC now owns 11,200 shares of the biotechnology company’s stock valued at $67,000 after buying an additional 7,600 shares during the last quarter. Finally, Clean Yield Group grew its stake in shares of Pacific Biosciences of California by 160.0% during the third quarter. Clean Yield Group now owns 13,000 shares of the biotechnology company’s stock valued at $67,000 after buying an additional 8,000 shares during the last quarter. Institutional investors and hedge funds own 71.58% of the company’s stock.

A number of research firms have recently commented on PACB. BidaskClub cut Pacific Biosciences of California from a “sell” rating to a “strong sell” rating in a research note on Tuesday, October 29th. ValuEngine raised Pacific Biosciences of California from a “sell” rating to a “hold” rating in a research note on Monday, November 4th. Finally, Piper Jaffray Companies raised Pacific Biosciences of California from a “neutral” rating to an “overweight” rating and set a $8.00 target price on the stock in a research note on Tuesday, October 15th. One equities research analyst has rated the stock with a sell rating, five have given a hold rating and one has given a buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and a consensus target price of $8.00.

PACB opened at $5.17 on Tuesday. The stock has a market cap of $792.33 million, a price-to-earnings ratio of -6.80 and a beta of 1.69. The stock’s 50 day moving average price is $4.98 and its 200-day moving average price is $5.66. Pacific Biosciences of California has a one year low of $4.37 and a one year high of $7.82. The company has a debt-to-equity ratio of 0.84, a quick ratio of 1.22 and a current ratio of 1.52.

Pacific Biosciences of California (NASDAQ:PACB) last released its earnings results on Thursday, November 7th. The biotechnology company reported ($0.19) EPS for the quarter, missing analysts’ consensus estimates of ($0.15) by ($0.04). The business had revenue of $21.92 million for the quarter, compared to the consensus estimate of $28.02 million. Pacific Biosciences of California had a negative net margin of 139.22% and a negative return on equity of 136.85%. As a group, analysts predict that Pacific Biosciences of California will post -0.71 earnings per share for the current fiscal year.

About Pacific Biosciences of California

Pacific Biosciences of California, Inc designs, develops, and manufactures sequencing systems to resolve genetically complex problems. The company's single molecule real-time (SMRT) sequencing technology enables single molecule real-time detection of biological processes. It offers PacBio RS II and Sequel Systems that conducts, monitors, and analyzes single molecule biochemical reactions in real time.

Read More: What is the price-sales ratio?

Institutional Ownership by Quarter for Pacific Biosciences of California (NASDAQ:PACB)

Receive News & Ratings for Pacific Biosciences of California Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pacific Biosciences of California and related companies with MarketBeat.com's FREE daily email newsletter.